Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis
MetadataShow full item record
Autotaxin has been associated with liver disease severity and transplant-free survival. This study aimed to validate autotaxin as a biomarker in two cohorts of Norwegian large-duct PSC patients, one discovery panel (n=165) and one validation panel (n=87). Serum activity of autotaxin was measured in diluted sera by a fuorometric enzymatic assay. Patients reaching an end-point, liver transplantation or death, (discovery panel: n=118 [71.5%]; validation panel: n=35 [40.2%]), showed higher autotaxin activity compared with the other patients, P<0.001 and P=0.004, respectively. Kaplan-Meier survival analyses showed a strong association between increasing autotaxin activity and shorter liver transplant-free survival (discovery panel: P<0.001, validation panel: P=0.001). There was no relationship between autotaxin activity and the presence of infammatory bowel disease or occurrence of hepatobiliary malignancy. In a multivariable analysis, high autotaxin activity was associated with an increased risk of liver transplantation or death (hazard ratio 2.03 (95% confdence interval 1.21–3.40), P<0.01), independent from Mayo risk score, an in-house enhanced liver fbrosis score and interleukin-8 in serum. In conclusion, increased serum autotaxin activity is associated with reduced liver transplantfree survival independent from Mayo risk score and markers of infammation and fbrosis.
CitationDhillon AK, Kremer, Kummen M, Boberg KM, Elferink, Karlsen HT, Beuers U, Vesterhus M, Hov JR. Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Scientific Reports. 2019;9:8450.
Copyright The Author(s) 2019